S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)

FDA halts use of antibody drugs that don't work vs. omicron


A doctor holds a Regeneron monoclonal antibody infusion bag during a news conference Thursday, Aug. 19, 2021 at a hospital in Fort Lauderdale, Fla. On Monday, Jan. 24, 2022, the Food and Drug Administration said COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the dominant omicron variant. (Joe Cavaretta/South Florida Sun-Sentinel via AP, File)

WASHINGTON (AP) — COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.

The Food and Drug Administration said it was revoking emergency authorization for both drugs, which were purchased by the federal government and have been administered to millions of Americans with COVID-19. If the drugs prove effective against future variants, the FDA said it could reauthorize their use.

The regulatory move was expected because both drugmakers had said the infusion drugs are less able to target omicron due to its mutations. Still, the federal action could trigger pushback from some Republican governors who have continued promoting the drugs against the advice of health experts.

Omicron’s resistance to the two leading monoclonal antibody medicines has upended the treatment playbook for COVID-19 in recent weeks.

Doctors have alternate therapies to battle early COVID-19 cases, including two new antiviral pills from Pfizer and Merck, but both are in short supply. An antibody drug from GlaxoSmithKline that remains effective also is in short supply.

The drugs are laboratory-made versions of virus-blocking antibodies. They are intended to head off severe disease and death by supplying concentrated doses of one or two antibodies early in an infection. Then-President Donald Trump received Regeneron's antibody combination after he tested positive for the coronavirus in 2020.

The FDA noted in its decision that omicron accounts for more than 99% of U.S. infections, making it “highly unlikely” the antibodies would help people now seeking treatment. The agency said restricting their use would also eliminate unnecessary drug side effects, including allergic reactions.

The U.S. government temporarily stopped distributing the two drugs in late December, as omicron was racing across the country to become the dominant variant. But officials resumed distribution after complaints from Republican governors, including Florida’s Ron DeSantis, who claimed that the drugs continued to help some omicron patients.


DeSantis has heavily promoted antibody drugs as a signature part of his administration's COVID-19 response, setting up infusion sites and lauding them at news conferences, while opposing vaccine mandates and other public health measures. Texas Gov. Greg Abbott has also launched state-sponsored infusion sites.

The drugs are not a substitute for vaccination and are generally reserved for people who are the most vulnerable, including seniors, transplant recipients and those with conditions like heart disease and diabetes.

Since early January, the U.S. government has shipped enough doses of the two antibodies to treat more than 300,000 patients.

Both Regeneron and Lilly previously announced they were developing new antibodies that target omicron.

The move comes days after regulators broadened the use of remdesivir — the first drug approved for COVID-19 — to treat more patients.

On Friday, the FDA expanded the antiviral’s approval to include adults and children with early COVID-19 who face a high risk of ending up in the hospital. Remdesivir previously had been limited to hospitalized patients.

An influential panel of federal experts had already recommended using the infused drug to try to head off hospitalization. The same guidelines from the National Institutes of Health panel recommend against continued use of Lilly and Regeneron’s antibody drugs due to their reduced effectiveness against omicron.

Still, many hospitals will face challenges in ramping up remdesivir treatments. The drug requires three consecutive IV infusions over three days, when used for nonhospitalized patients. That time-consuming process won’t be an option for many over-capacity hospitals facing staff shortages.

The FDA made its decision based on a 560-patient study that showed a nearly 90% reduction in hospitalizations when remdesivir is given within seven days of symptoms. The study predates the omicron variant but, like other antivirals, remdesivir is expected to maintain its performance against the latest variant.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Eli Lilly and (LLY)
2.7549 of 5 stars
$308.08+2.6%1.27%49.14Moderate Buy$317.00
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Eli Lilly and right now?

Before you consider Eli Lilly and, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and wasn't on the list.

While Eli Lilly and currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastInvesting in What You Know Has Changed

What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.